Evans M P, Webb M J, Gaffey T A, Katzmann J A, Suman V J, Hu T C
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Cancer. 1995 May 1;75(9):2295-8. doi: 10.1002/1097-0142(19950501)75:9<2295::aid-cncr2820750918>3.0.co;2-c.
Most cases of granulosa cell tumor of the ovary are characterized by relatively good outcome; however, some tumors behave aggressively, and some tend to recur many years after the initial diagnosis. Because DNA ploidy has been shown to predict biologic behavior better than conventional prognostic variables in many types of genitourinary tumors, the DNA ploidy of granulosa cell tumors was studied to determine if this test correlates with recurrence or survival.
Paraffin embedded tissue blocks were available from the primary ovarian tumors of 40 patients. DNA ploidy, percent S-phase fraction, and proliferative index were determined for each sample and were compared with patient outcome.
Of the 40 tumors, 33 were DNA diploid, 5 were DNA near diploid/aneuploid, and 2 were aneuploid. The Kaplan-Meier estimate of the probability of tumors not recurring within 5 years postoperatively was 0.907 (95% confidence interval: 0.811, 1.00).
There is insufficient evidence to claim that the DNA pattern is associated with morphology, stage of disease at diagnosis, or tumor size or that either survival or progression free survival differs with respect to any of the conventional prognostic factors considered. However, progression free survival tends to be shorter for those whose maximal tumor dimension was at least 10 cm (borderline significance, P = 0.0597), and survival time tends to be shorter for those with a high proliferative index (P = 0.0008).
大多数卵巢颗粒细胞瘤病例预后相对较好;然而,一些肿瘤具有侵袭性,且有些在初次诊断多年后容易复发。由于在许多类型的泌尿生殖系统肿瘤中,DNA倍体已被证明比传统预后变量能更好地预测生物学行为,因此对颗粒细胞瘤的DNA倍体进行研究,以确定该检测是否与复发或生存相关。
有40例患者原发性卵巢肿瘤的石蜡包埋组织块。测定每个样本的DNA倍体、S期分数百分比和增殖指数,并与患者的预后进行比较。
40个肿瘤中,33个为DNA二倍体,5个为DNA近二倍体/非整倍体,2个为非整倍体。术后5年内肿瘤不复发概率的Kaplan-Meier估计值为0.907(95%置信区间:0.811,1.00)。
没有足够的证据表明DNA模式与形态、诊断时疾病分期或肿瘤大小有关,也没有证据表明在所考虑的任何传统预后因素方面生存或无进展生存存在差异。然而,最大肿瘤直径至少为10 cm的患者无进展生存期往往较短(临界显著性,P = 0.0597),增殖指数高的患者生存时间往往较短(P = 0.0008)。